Stockscreener 앱 받기
8.4134
2.47%
0.2034
전일 마감가:
$8.21
열려 있는:
$8.26
하루 거래량:
886.19K
Relative Volume:
0.13
시가총액:
$1.95B
수익:
$509.86M
순이익/손실:
$165.35M
주가수익비율:
12.41
EPS:
0.6779
순현금흐름:
$107.55M
1주 성능:
+4.38%
1개월 성능:
+1.73%
6개월 성능:
-57.36%
1년 성능:
-59.57%
1일 변동 폭
$8.23
$8.51
1주일 범위
$8.02
$8.895
52주 변동 폭
$7.2101
$20.97
Adma Biologics Inc Stock (ADMA) Company Profile
명칭
Adma Biologics Inc
전화
(201) 478-5552
주소
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
8.415 | 1.90B | 509.86M | 165.35M | 107.55M | 0.6779 |
VRTX
Vertex Pharmaceuticals Inc
|
450.31 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.56 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
880.79 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.28 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
159.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Buy |
| 2026-03-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-07-19 | 재개 | Raymond James | Strong Buy |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2021-11-11 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-04 | 개시 | Jefferies | Buy |
| 2019-04-15 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-07 | 재개 | H.C. Wainwright | Buy |
| 2017-12-11 | 재확인 | Maxim Group | Buy |
| 2017-11-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | 업그레이드 | Maxim Group | Hold → Buy |
| 2016-08-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2016-07-25 | 재확인 | Maxim Group | Buy |
| 2015-05-13 | 재확인 | Maxim Group | Buy |
| 2014-12-08 | 개시 | Oppenheimer | Outperform |
| 2014-12-01 | 재확인 | Maxim Group | Buy |
모두보기
Adma Biologics Inc 주식(ADMA)의 최신 뉴스
ADMA Biologics Fair Value call saved investors from 40% decline By Investing.com - Investing.com Canada
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lost Money on ADMA Biologics, Inc. (ADMA)? Join Class Action Before August 10, 2026Contact Levi & Korsinsky - ACCESS Newswire
Nomura VIP Small Cap Growth Series's ADMA Biologics Inc(ADMA) Holding History - GuruFocus
ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead the ADMA Biologics Class Action Lawsuit - The Malaysian Reserve
ADMA Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against ADMA Biologics, Inc. - PR Newswire
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - StreetInsider
ADMA Biologics Faces Securities Fraud Lawsuit - Intellectia AI
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action - Benzinga
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, - GlobeNewswire
DEADLINE ALERT for VIA, Z, and ADMA: The Law Offices of - GlobeNewswire
Law Offices of Frank R. Cruz Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action - Business Wire
$ADMA Class Action Alert: ADMA Biologics Channel Stuffing - GlobeNewswire
$ADMA Lawsuit: ADMA Biologics Channel Stuffing Allegations Trigger Securities Fraud Class ActionInvestors Notified of August 10 Court Deadline - ACCESS Newswire
ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence - Stocktwits
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - lincolnjournal.com
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
INVESTOR ALERT: Securities Class Action Filed Against ADMA Biologics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP - mydailyrecord.com
ADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
ADMA Biologics Faces Securities Fraud Lawsuit Amidst Stock Decli - GuruFocus
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
ADMA Faces Securities Fraud Lawsuit Over Alleged Revenue Inflati - GuruFocus
ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substan - GuruFocus
ADMA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - Bluefield Daily Telegraph
Law Offices of Howard G. Smith Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action - lincolnjournal.com
$ADMA Breaking News: ADMA Biologics Sued for Securities Fraud after Channel Stuffing Claims Lead to 16% Stock Drop – Investors Notified to Contact BFA Law - The Malone Telegram
ADMA INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire
Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit - Business Wire
Class Action Lawsuit Filed Against ADMA Biologics - Intellectia AI
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel ... - Caledonian Record
ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities Fraud; Investors Should Contact Block ... - Caledonian Record
ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities - GlobeNewswire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ADMA Biologics, Inc. Investors – ADMA - The Joplin Globe
Raymond James Initiates ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $21 - Moomoo
ADMA: Analyst Upgrades Stock with $21 Price Target - GuruFocus
Raymond James initiates ADMA Biologics stock coverage with outperform rating - Investing.com Nigeria
ADMA Biologics Investigation: ADMA Biologics (ADMA) - GlobeNewswire
(ADMA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ADMA Biologics Inc (ADMA) Stock Analysis: Exploring A 110% Potential Upside In Biotech - DirectorsTalk Interviews
ADMA News | ADMA BIOLOGICS INC (NASDAQ:ADMA) - ChartMill
Assessing ADMA Biologics (ADMA) Valuation After Legal Probes Short Seller Claims And Guidance Withdrawal - Sahm
ASCENIV growth lifts ADMA Biologics (NASDAQ: ADMA) margins and buybacks - Stock Titan
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - ACCESS Newswire
ADMA Biologics earnings on deck amid channel stuffing scrutiny - Investing.com
Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Earnings call transcript: ADMA Biologics misses Q1 2026 forecasts, faces competitive pressures - Investing.com
US High Growth Tech Stocks with Promising Potential - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
PFM Health Sciences, LP's ADMA Biologics Inc(ADMA) Holding History - GuruFocus
ADMA Legal Claims: ADMA Biologics may have Misrepresented - GlobeNewswire
Adma Biologics Inc (ADMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Adma Biologics Inc 주식 (ADMA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Grossman Jerrold B | Director |
May 12 '26 |
Buy |
8.01 |
12,500 |
100,125 |
513,884 |
| Grossman Jerrold B | Director |
May 11 '26 |
Buy |
8.01 |
12,500 |
100,125 |
501,384 |
| Guiheen Lawrence P. | Director |
Mar 13 '26 |
Option Exercise |
3.66 |
30,000 |
109,800 |
135,520 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,133,777 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Sale |
15.16 |
21,000 |
318,360 |
2,112,777 |
1.35%
0.76%
자본화:
|
볼륨(24시간):